Bionutrics Subsidiary Awarded SBIR Grant for Diabetes Research.PHOENIX--(BUSINESS WIRE)--Oct. 14, 1999-- Bionutrics, Inc., (Nasdaq: BNRX) announced today that its wholly owned R&D subsidiary, LipoGenics, Inc., has been awarded a Phase I Small Business Innovation Research (SBIR SBIR Small Business Innovation Research (program/grant) SBIR Space Based Infra-Red SBIR Speaker-Boundary Interference SBIR Site Backsurface-referenced Ideal Plane/Range (silicon wafers) ) grant from the National Heart, Blood and Lung Institute. This grant, entitled "A Novel Tocotrienol for Treating Diabetic Dyslipidemia," will support studies to evaluate alterations in blood lipid lipid Any of a diverse class of organic compounds, found in all living things, that are greasy and insoluble in water. One of the three large classes of substances in foods and living cells, lipids contain more than twice as much energy (calories) per unit of weight as the and other chemistry profiles by one of its patented tocotrienol compounds. Tocotrienols are the members of the vitamin E vitamin E or tocopherol Fat-soluble organic compound found principally in certain plant oils and leaves of green vegetables. Vitamin E acts as an antioxidant in body tissues and may prolong life by slowing oxidative destruction of membranes. family and differ from the more common vitamin E tocopherols in their chemical structure. Abnormalities in particular blood chemistry parameters are commonly associated with diabetes and represent a risk factor for cardiovascular disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease , the leading cause of death in diabetic individuals. The SBIR-funded research will be conducted in LipoGenics' research laboratory located in Worcester, Massachusetts. LipoGenics President, F. Howard Schneider, Ph.D., commented: "This grant will support Bionutrics' and LipoGenics' ongoing research to substantiate To establish the existence or truth of a particular fact through the use of competent evidence; to verify. For example, an Eyewitness might be called by a party to a lawsuit to substantiate that party's testimony. the value of tocotrienols in prevention or treatment of specific disease conditions, such as diabetes. The focus on lipid abnormalities in diabetes is a logical extension of our continuing effort to develop products for improving cardiovascular health. We view our success in obtaining the SBIR award as an important milestone in our product development program." Bionutrics is an emerging biopharmaceutical company founded to discover and develop novel biologically active compounds derived from natural sources. Natural, biologically active compounds have potential applications as ethical drugs as well as functional nutrition ingredients. Bionutrics introduced its first tocotrienol-based product, evolvE(R) Advanced Cardiovascular Dietary Supplement Noun 1. dietary supplement - something added to complete a diet or to make up for a dietary deficiency diet - a prescribed selection of foods vitamin pill - a pill containing one or more vitamins; taken as a dietary supplement , and is presently developing additional proprietary functional nutrition ingredients and pharmaceutical products with applications beyond cardiovascular health. "Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: This release contains forward looking statements that are subject to risks and uncertainties, including, but not limited to, the impact of competitive products and pricing, product demand and market acceptance, new product development, reliance on key strategic alliances, availability of raw materials, the regulatory environment and governmental approval processes, fluctuations in operating results and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion